ArticleInternational journal of environmental research and public health2022
Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China.
Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07430501 (AcceleRating the Translation of Virtual Twins Towards a pErsonalised Management of Steatotic Liver Patients), which is not on this map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AcceleRating the Translation of Virtual Twins Towards a pErsonalised Management of Steatotic Liver Patients
Who cites it
39 citing papers in PubMed.
- Article
- Development and validation of a risk model for non-fatty chronic liver disease in middle-aged and older adults with metabolic syndrome.BMC gastroenterology · 2026Article
- Circulating MicroRNA Profiling for Phenotypic Stratification in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Candidate-Based Study.Current issues in molecular biology · 2026Article
- Article
- Prevalence and factors associated with metabolic dysfunction-associated fatty liver disease in a multiethnic Asian country.Scientific reports · 2026Article
- Use of Artificial Intelligence-Assisted Histopathology for Evaluation of Sex-Specific Progression and Regression of Hepatocellular Carcinoma Related to Metabolic Dysfunction-Associated Fatty Liver Disease.Diagnostics (Basel, Switzerland) · 2026Article
- Body mass index is closely correlated with blood lipids, blood pressure, serum uric acid and hepatic steatosis in middle-aged and elderly hypertensive health examinees.American journal of translational research · 2026Article
- Non-lean versus lean MASLD: associations with advanced cardiovascular-kidney-metabolic syndrome in adults with type 2 diabetes mellitus, a cross-sectional study.Frontiers in endocrinology · 2026Article
- Serum Extracellular Vesicles as Pathogenetic Signals in Obese and Lean Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.Metabolites · 2025Article
- Asymmetric Dimethylarginine: A Never-Aging Story.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2025Review
- Neutrophil Extracellular Traps (NETs) as a Potential Target for Anti-Aging: Role of Therapeutic Apheresis.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2025Review
- Prevalence, demographic characteristics and clinical profile of metabolic dysfunction-associated fatty liver disease among adult patients attending tertiary hospitals in Dodoma, Tanzania. a cross-sectional study.BMC gastroenterology · 2025Article
- Prevalence of metabolic dysfunction-associated fatty liver disease among health check-up attendees: A retrospective study conducted in Vietnam.World journal of gastroenterology · 2025Article
- Metabolic dysfunction-associated fatty liver disease (MAFLD) in the adult population attending a health check-up program in Thailand: prevalence and fibrosis status.Scientific reports · 2025Article
- Frequency and risk factors of metabolic associated fatty liver disease among medical students in Egypt.Scientific reports · 2025Article
- Metabolic dysfunction-associated fatty liver disease indicates more hepatic fibrosis than nonalcoholic fatty liver disease.Medicine · 2025Article
- Overweight andFrontiers in cellular and infection microbiology · 2025Article
- Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.Annals of medicine · 2024Article
- Effects of MAFLD defined by fatty liver index or ultrasonography on kidney function decline in the general population.Scientific reports · 2024Article
- Assessing the Prognostic Utility of the New Mayo Adhesive Probability Score in East Asian Populations and its Correlation with Metabolic-Associated Fatty Liver Disease.Physiological research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of metabolic-associated fatty liver disease (MAFLD) is rarely reported in Beijing. The goal of this study was to estimate the prevalence and risk factors of MAFLD among Beijing adults aged ≥25 years old. A cross-sectional, community-based survey with multistage stratified cluster sampling was used. Demographic, transient elastography (TE), biochemical and blood examination information was collected in all the subjects in this study. The prevalence of MAFLD was 32.40% (23,832/73,566). Risk factors independently associated with MAFLD included male gender (OR = 1.47, 95%CI, 1.43-1.52), urban residence (OR = 1.06, 95% CI, 1.02-1.10), older age (30-39 years: OR = 1.29; 40-49 years: OR = 1.43; 50-59 years: OR = 1.09; ≥60 years: OR = 1.52) and lower education (middle school: OR = 2.03; high school: OR = 1.89; undergraduate: OR = 1.69). MAFLD was more common in females than in males after 50 years of age. Lean/normal weight MAFLD patients account for approximately 3.04% (724/23,832) of MAFLD. Compared to non-MAFLD subjects, the lean/normal MAFLD patients had a higher prevalence of hypertension and diabetes, and had a higher degree of hepatic steatosis and liver function enzymology parameters (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.